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Antimicrobial resistance (AMR) is a public health threat;
infections with resistant organisms are estimated to
cause over 650.000 infections and over 30.000 deaths in
Europe1. AMR is associated with antibiotic consumption:
appropriate prescribing of antibiotics is key in combating
AMR2,3. To fight this threat, it has been suggested that
point-of-care diagnostics to inform antibiotics
prescribing are an important tool in reducing antibiotics
prescriptions.
We searched the literature
comprehensively through the PUBMED,
Web of Science and EMBASE databases,
as well as grey literature for the period
2000-2018. We included economic
evaluations for diagnostic strategies for
infectious disease in all geographic
areas. Studies dealing with (population)
screenings or disease monitoring were
explicitly excluded. Data extraction was
based on the CHEERS checklist4, using a
standardized digital (Google) form, with




Most cost-effectiveness analyses dealing with diagnostics
are for certain types of respiratory tract infections: such
as general respiratory tract infections, influenza or
tuberculosis. Sexual transmitted disease, malaria and
gastroenteritis (e.g. helicobacter infections) are also
common disease groups.
Although bacterial or viral resistance is often discussed in
the included papers, it is rarely included in the analysis.
Examples of methods to include resistance are: an ICER
with prescriptions saved as an outcome; calculating the
threshold cost of resistance that would change the
conclusion of cost-effectiveness; or a point estimate of
resistant pathogens.
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The flow diagram of included articles is
shown above. Most papers are set in the
primary care setting, followed by the
hospital setting. A large majority of
papers analyzed use a decision tree
model for the calculation of quality-
adjusted life years (QALYs) and costs.
Often, these models use shorter time
horizons, (e.g. one flu season), rather
than a lifetime approach. The disease
types investigated are shown in the pie
chart below. Looking at the author’s
conclusions (see figure to the left),
influenza diagnostics are not cost-
effective in 50% of the articles, but for
respiratory infections, improved




















(n =  373 )
Population 
screenings (n = 218)
(Other) no 
diagnostic 
strategies (n = 61)
No cost-
effectiveness 
analysis (n = 35)Records 
excluded
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Flow chart of paper inclusion
Pie chart of disease types included in systematic review
With the objective of knowing the state of the art on
diagnostic, health-economic models, we reviewed cost-
effectiveness analyses (CEAs) on diagnostics for




I n fe c t i ou s d i se a se se ss i on
Nove mbe r  5




































General conclusions of articles in two disease areas*
* Preliminary results
* no exhaustive list of exclusion criteria is provided here
